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I. INTRODUCTION
Amyloid brils are ordered polypeptide aggregates that have been implicated in several
neurodegenerative pathologies, such as Alzheimer's, Parkinson's, Huntington's and prion
diseases1,2, and, more recently, also in biological functionalities3{5. These ndings have
paved the way for a wide range of experimental and computational studies aimed at
understanding the details of the bril formation mechanism. Computer simulations using
low-resolution models, which employ a simplied representation of protein geometry and
energetics, have provided insights into the basic physical principles underlying protein
aggregation in general6{8 and ordered amyloid aggregation9{15. For example, Dokholyan
and coworkers have used the Discrete Molecular Dynamics method16,17 to shed light
on the mechanisms of protein oligomerization18 and the conformational changes that
take place in proteins before the aggregation onset19,20. One challenging observation,
which is dicult to observe by computer simulations, is the wide range of aggregation
scenarios emerging from a variety of biophysical measurements21,22. Atomistic models
have been employed to study the conformational space of amyloidogenic polypeptides
in the monomeric state23{25, the very initial steps of amyloid formation26{32, and the
structural stability of bril models33{35. However, all-atom simulations of the kinetics of
bril formation are beyond what can be done with modern computers.
To overcome such computational limitations, simplied models have been developed
and used to investigate the kinetics and pathways of oligomerization and bril formation
at dierent levels of resolution36. In this chapter we rst review briey the simplied
models of aggregation. We then present our coarse-grained phenomenological (CGF)
model of an amphipathic peptide37, and its use for studying kinetics and thermodynamics,
both in bulk conditions and in presence of other simplied (macro)molecules.
II. COARSE-GRAINED MODELS
In coarse-grained models, the complexity of a system (and therefore the computa-
tional cost) is reduced by grouping atoms into larger units or \beads", whose mutual
interactions are usually approximated by a potential of mean force38. Several coarse-
grained models of dierent resolutions have been developed to study aggregation (see
Fig.1). Zhang and Muthukumar39 have created a cuboid model able of reproducing the
features of a nucleation-limited aggregation process. With their so-called \tube" model,
Auer and coworkers40 have shed light upon the conversion of a disordered aggregate into
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an aggregating nucleus. Higher resolution models like the one developed by Thirumalai
and collaborators41 or the PRIME model of Nguyen and Hall42 have also showed disor-
dered aggregates in the early steps of aggregation. Several aggregation scenarios have
been described with the three-bead model of Shea and coworkers43. In their model, the
variation of a parameter related to the dihedral exibility is able to reproduce dierent
aggregation kinetics and metastable intermediates (amorphous and -barrel like), which
is in part similar to the CGF model37. The main dierence between the Shea and CGF
models is that the former is based on a coarse-graining from an atomistic description
(i.e., "bottom-up" development), whereas the CGF model is purely phenomenological
("top-down") as explained in the next section.
III. THE CGF (COARSE-GRAINED PHENOMENOLOGICAL) MODEL
The coarse-grained model of an amphipathic peptide developed for studying aggre-
gation kinetics and thermodynamics is a compromise between mesoscopic detail and
computational eciency. It must be stressed that this simplied model does not repre-
sent a particular protein sequence, i.e., it has not been generated by grouping into larger
beads the atomic structure of a given (poly)peptide. It rather was designed from scratch
for emulating the main experimental ndings on bril formation kinetics.
The peptide is approximated by 10 spherical beads, four of which represent the \back-
bone" (small beads) and six the \side chain" (large beads) (Fig. 2, top). The \backbone"
beads carry partial charges of 0:4e, thereby generating two dipoles; this part of the
monomer is designed to interact specically by intermolecular dipole-dipole interactions.
The large beads interact only by van der Waals forces. The non-bonding interaction cut-
o is set equal to 20 A. The monomer displays an amphipathic moment, since eight of the
ten beads have less favorable van der Waals interactions than the remaining two beads
(black spheres in Fig. 2, top). The amphipathicity of the \molecule" allows the forma-
tion of amorphous aggregate, such as micellar oligomers, and the assembly of brils. In
both of these types of aggregates, the hydrophobic spheres are buried and the hydrophilic
spheres are exposed. The micellar oligomers are spherical and uid-like, while the brils
are ordered and rigid (see below).
The monomer can change its conformation by rotating around the internal dihedral
dened by the small beads (Fig. 2, bottom). Using a one-dimensional spline function44, a
dihedral potential was designed with only two minima separated by a barrier (see Fig. 3).
The only parameter that rules the relative populations of the amyloid-prone and amyloid-
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protected states is the energy dierence dE = E   E between the conformation with
perpendicular dipoles (E), which prevents ordered aggregation, and the conformation
with parallel dipoles, which is prone to form brils (E). The use of a single parameter
to model a complex process was inspired by the work of Zhou and Karplus, who have
analyzed the folding kinetics of a model protein by varying a single parameter and shown
that it is possible to recover several folding scenarios45.
IV. AGGREGATION OF THE CGF PEPTIDE MODEL IN BULK SOLUTION
Unless specied explicitly, simulations are started from 125 monodispersed monomers
of the CGF peptide in a cubic box with a size of 290 A, corresponding to a concentration of
8.5 mM. After minimization and equilibration, simulations are performed with Langevin
dynamics at 310 K with a very small friction coecient of 0.01 ps 1 using CHARMM46.
A. Aggregation kinetics and pathways
The range of aggregation kinetics of the CGF model is shown in Fig. 4, where the
normalized degree of polymerization as a function of time is plotted for dierent values
of the amyloidogenic propensity dE. The extent of aggregation is controlled by counting
the number of polar contacts: a polar contact is formed whenever two dipoles of dierent
monomers are closer than 5 A. Three dierent kinetic phases are visible: lag, elongation,
and nal monomer-bril equilibrium. The variable length of the lag phase and the higher
heterogeneity at longer lag times are indicative of a stochastic nucleation48. Fibril forma-
tion is much slower for the -unstable models (dE = -2.5 and -2.25 kcal/mol) than the
-stable models (dE = -1.0 and 0.0 kcal/mol). Both the lag phase and the elongation
kinetics are aected by the single free parameter dE of the CGF model. Interestingly,
the kinetics of aggregation are qualitatively consistent with the experimental data on
single-point mutants of A40 (Ref.
49), which have shown that the -sheet propensity and
hydrophobicity aect the features of the aggregation process. This comparison shows
that although the CGF model does not represent any particular polypeptide sequence,
variations of the single parameter dE emulate the behavior observed for (slightly) dier-
ent amyloidogenic sequences. Moreover, the anticorrelation between the length of the lag
phase and the rapidity of the bril elongation has also been observed experimentally on
several samples prepared from amyloidogenic (poly)peptide sequences47.
The distribution function p(N) of the oligomer size N evaluated at the lag phase or
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at the nal equilibrium is depicted in Fig. 5. The monomer peak ranges from N = 1 to
N = 7, the micellar peak from N = 8 to N = 60, and the brillar peak from N = 61
to N = 125. The micellar peak is present for the dE = -2.5 kcal/mol model at the lag
phase, but disappears at the nal equilibrium, where the bril and the monomers are the
only co-existing species. For the -stable potential dE = 0.0 kcal/mol, the micellar peak
is not observed at any concentration value. Indeed, a comparison of the lag times with
the times of micelle formation (Fig. 6) shows that the bril formation kinetics of the -
unstable and -stable models are, respectively, slower and faster than micelle formation.
In fact, micelles are intermediates consisting mainly of monomers in the  state, whereas
the polymerization of -stable monomers directly yields brils.
This observation is conrmed also by the analysis of aggregation pathways50. A total of
100 Langevin dynamics simulations for dierent values of dE were clustered according to
three progress variables: the size of the largest aggregate Nla, the number of monomers
in the -state within the largest aggregate Nla, and the number of protolaments in
the largest aggregate Npfla , where a protolament is dened as a le of monomers with
intermolecular dipolar interactions parallel with its axis. The aggregation state network
(Fig. 7) is a graph in which the states and direct transitions observed during the Langevin
dynamics simulations are displayed as nodes and links, respectively. Furthermore, the size
of each node reects the statistical weight of the corresponding state. Micellar oligomers
(white nodes, Nla  20, Npfla =0) and brils (red nodes, Nla  100, Npfla =4) are the most
populated states during the lag phase and the nal equilibrium, respectively. Strikingly,
a greater variety of aggregation mechanisms emerges for the poorly amyloidogenic CGF
peptide model (see Fig. 7, bottom) than the highly amyloidogenic CGF peptide model
(see Fig. 7, top). Indeed, the former shows the presence of intermediates, i.e., protobrils
consisting of only two (green nodes) or three (blue nodes) protolaments. According to
this analysis, it is reasonable to expect that a mutation that decreases the -aggregation
tendency could result in a greater variety of prebrillar aggregates, as in the case of
the Arctic mutant (E22G) of the Alzheimer's A peptide and the A30P mutant for -
synuclein, for which a more pronounced in vitro formation of oligomers and protobrils
was observed51,52.
B. Mechanism of nucleation
The nucleation properties of the CGF model are investigated by evaluating the prob-
ability of bril formation for -subdomains, i.e., the clusters of interacting -monomers.
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The nucleus, dened as the oligomer containing a -subdomain with a 50% probability
to form a bril, shows an increasing size upon destabilization of the -state. Signicantly
dierent nucleation mechanisms are observed upon variation of the amyloidogenicity pa-
rameter dE (Fig. 8). For high values of the amyloidogenic propensity ( 2:0  dE  0.0
kcal/mol), the nucleus size is sub-micellar, and nucleation is simply the aggregation of
monomers in the -state. On the contrary, for poorly amyloidogenic peptides, nucleus
formation requires either spatial proximity of several monomers in the -state (dE =
-2.25 kcal/mol) within a micelle or collision of two peptide micelles with merging of their
-subdomains (dE = -2.5 kcal/mol). The variety of aggregation scenarios is also ob-
served experimentally. An unstructured peptide with a marginally stable -prone state
like A40 (Ref.
53,54) visits oligomeric intermediates in the lag phase, and has a very weak
dependence of the elongation rate on concentration due to the monomer-micelle equilib-
rium. This mechanism corresponds to the nucleated conformational conversion proposed
by Serio et al.55. On the other hand, a functional and non-pathological amyloid in mam-
malians56 lacks on-pathway intermediates and corresponds to the highly amyloidogenic
CGF peptide model. Once more, by varying the only free parameter dE of the CGF
model, it is possible to describe the aggregation properties of a wide and diverse range
of (poly)peptide sequences.
C. Concentration eects
The dE parameter of the CGF model has a strong inuence on the concentration
dependence of the bril formation kinetics. In agreement with the above-mentioned
mechanism of nucleation, CGF peptides poorly prone to aggregation nucleate only at
concentration values larger than the critical concentration of peptide micelle formation,
whereas CGF peptides with a high value of amyloidogenicity nucleate even at lower con-
centrations (Fig. 9, left). Furthermore, the dependence of the elongation rate on the
concentration is only marginal at low amyloidogenic tendency (Fig. 9 (b)). The reduced
concentration dependence originates from competitive polymerizations, i.e., the elonga-
tion of the bril and the presence of micellar oligomers. This observation is a consequence
of the monomer-micelle equilibrium of the CGF peptide model, which maintains a nearly
constant concentration of isolated monomers57.
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D. Amyloid bril polymorphism
Experiments based on electron and atomic force microscopy as well as solid-state
NMR spectroscopy revealed that changing the samples conditions, such as the pH59 or
the cosolvent concentration60, or introducing a mechanical perturbation61,62 results in
dierent amyloid bril morphologies. Furthermore, even within the same sample, a num-
ber of coexisting morphologies can be detected59,63. Recently, it was observed that the
CGF peptide model is able to generate brils with distinct morphologies64. Interestingly,
the populations of the dierent morphologies are strongly and nontrivially inuenced
by the amyloidogenic propensity dE, and two main mechanisms for bril morphogenesis
emerge. When the CGF peptide is highly prone to aggregate (dE = -1.5, -2.0 kcal/mol),
the morphogenesis is under thermodynamic control, meaning that the morphology with
the highest stability will emerge with the highest probability. In contrast, when the
CGF peptide has a low amyloidogenic tendency (dE = -2.25, -2.5 kcal/mol), the bril
morphogenesis is under kinetic control. The morphologies that nucleate more readily are
not necessarily the most stable ones, but those whose precursors are kinetically more
accessible, as revealed by the free energy proles of the brillation64. For the low amy-
loidogenic scenario, the process of morphology dierentiation can be represented by a
branched tree (Fig. 10). During the lag phase, the micellar oligomers are in equilibrium
with the dispersed monomers. The early morphology dierentiation occurs at the nu-
cleation step, where the formation of the protobrillar intermediates is regulated by the
structural bifurcation of the nucleus. The 2PP and 3PP1 intermediates are competent
to 4PF1 brils, while the 3PP2 intermediate is competent to 4PF2(+,-) brils. Alterna-
tively, the presence of 3PP2+ and 3PP2- intermediates that are directly competent to
4PF2+ and 4PF2- brils, respectively, has been observed, although these pathways were
not quantitatively analyzed. Finally, the pathway of formation of 4PF3 brils was not
investigated in detail, due to the small number of nucleation events of this morphology.
The multiple-pathways process observed here has a close similarity with the scenario
described by Goldsbury et al.65, where two dierent morphologies of A have distinct
maturation pathways, either with or without the presence of metastable protobrils.
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V. AGGREGATION IN THE PRESENCE OF LIPID VESICLES AND INERT
CROWDERS
Amyloid aggregation in vivo does not occur in bulk solution. Rather, it takes place in
the extracellular space, whose composition includes metabolites and proteins, or within
the cell, which is usually densely occupied by (macro)molecules like proteins, nucleic acids,
and polysaccharides, as well as macromolecular assemblies and organelles66. Several
research groups have investigated the interactions between lipid vesicles and amyloid
aggregates67{69, whose accumulation on the surface of lipid bilayers was observed to cause
membrane damage. Aggregation has also been studied in crowded media70{72, where the
thermodynamics and kinetics of aggregation are expected to sensibly change.
A. Eect of lipid bilayers on CGF peptide aggregation
A three-bead model of a lipid molecule has been developed to study the CGF peptide
model aggregation kinetics in the presence of a lipid vesicle73,74. Several independent
Langevin simulations at 310 K have been performed for four values of dE with 125
peptides initially monodispersed in a cubic box of length 290 A and a preequilibrated
unilamellar bilayer vesicle made up of 1000 lipids. Depending on the lipid/peptide van
der Waals coupling parameter , between 50% and 80% of the CGF peptides are located
on the lipid vesicle surface after the initial equilibration phase, i.e., before bril formation
(Table 1).
The eect of lipid bilayers on aggregation kinetics for dierent values of amyloidogenic-
ity is reported in Table 2. Highly amyloidogenic peptides brillate more rapidly in the
presence of lipid vesicles than in their absence, while the opposite is observed for peptides
of low amyloidogenicity. The faster aggregation kinetics of highly amyloidogenic peptides
is a consequence of their higher eective concentration on the lipid bilayer relative to the
bulk. In contrast, despite the same increase of peptide concentration on the vesicle sur-
face, brillation of peptides with low amyloidogenic propensity is slower in the presence of
lipid vesicles. As mentioned in section III, peptides with low amyloidogenic potential can
brillate only after aggregating into spherical oligomeric intermediates with hydrophobic
interior and hydrophilic surface. In the simulations with lipids, such oligomeric interme-
diates form in the bulk but not on the vesicle. Fibrillation of low amyloidogenic peptides
therefore takes place in the bulk and is slower than in the absence of a vesicle due to
the lower eective concentration of peptides in the solvent. These simulation results are
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consistent with and explain the apparently contradictory experimental observations on
faster aggregation of the A(Ref.68) or -synuclein75 peptides in the presence of lipid sur-
faces and slower aggregation of insulin (which has lower amyloidogenicity)76, and have
been conrmed by recent studies on the aggregation properties of human islet amyloid
polypeptide hIAPP1 19 in presence of lipid vesicles77.
To investigate the inuence of the CGF peptides on the lipid bilayer, the simulations
were initiated with 20 spherical probes inside the vesicle. It was observed that leakage
from the lipid vesicle is enhanced during bril formation but not by the mature bril73.
More precisely, a comparison between the brillation and probe release rates (Fig. 11,
left) revealed that probe release is fastest during bril growth, whereas the kinetics of
probe release in the presence of mature brils is as slow as in the absence of peptides,
indicating that mature brils do not damage the integrity of the vesicle. Rather, the
ongoing process of aggregation on the vesicle results in bilayer surface defects. This
observation explains why for some amyloidogenic peptides there exist mutants that form
brils more rapidly and are more toxic than the wild-type peptides, even though their
brils are not toxic78. Moreover, these computational results are in agreement with the
experiments performed by Engel et al. on membrane damage caused by human islet
amyloid polypeptide bril growth69 (Fig. 11 right).
It has also been hypothesized that formation of toxic oligomers that induce membrane
leakage could be the result of a backward production of oligomers from the mature bril79.
Interestingly, by modulating the attraction between the CGF peptides and the membrane,
bril disaggregation into soluble backwards oligomers has been observed74. The disag-
gregation process is driven by entropy and results in soluble protobrillar oligomers. The
protobrillar oligomers are larger, more ordered, and more stable than those observed
during the aggregation process and, importantly, are not detected in disaggregation sim-
ulations carried out in bulk solution, i.e., in the absence of lipid vesicles.
B. Eect of surfactants on CGF peptide aggregation
Surfactant molecules have been modeled using a similar three-bead model as that
used for lipids. The surfactant model diers from lipid models used previously in two
parameters (Table 1): the minimum of the van der Waals energy of the two hydrophobic
beads is less favorable, and the radius of the hydrophilic bead is larger to enable the
formation of amorphous aggregates. Using these parameters, the surfactant solution
is not dominated by a micellar phase. Rather, the surfactants are organized either as
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dispersed monomers or disordered aggregates80.
In the absence of surfactants, all peptide models form brils within 1 s without any
discernible lag phase (Fig. 12, dotted lines). At a surfactant:peptide ratio of 8:1, the bril
formation kinetics of peptides with dE = -1.5 kcal/mol are almost unaected, whereas
already at a ratio of 4:1 the ordered self-assembly of peptides with dE < -2.0 kcal/mol is
signicantly slower (Fig. 12, solid lines) mainly because of a longer lag phase. Moreover,
for low-amyloidogenic peptides (dE  -2.0 kcal/mol) no brillation is observed within
the simulation length of 2 s at a surfactant:peptide ratio of 8:1, but instead oligomers
of  40 peptides form. These simulation results show that at a 4-fold molar excess of
surfactant, the inhibition of brillation already depends strongly on the amyloidogenicity
of the CGF peptide model.
C. Macromolecular crowding eect on CGF peptide aggregation
Simulations with the CGF peptide model together with softly repulsive spheres have
been carried out to assess the inuence on the aggregation kinetics of excluded volume
and hindered peptide diusion due to macromolecular crowding 81. As in the case of
lipid-bilayer vesicles, the net eect of macromolecular crowding crucially depends on
the amyloidogenicity tendency of the CGF peptide. For peptides with low aggregation
propensity, the self-association process is transition-state limited, where the kinetic bot-
tleneck is the formation of the bril nucleus. In this case, since the oligomers, including
the nucleus, are thermodynamically favored (with respect to the isolated monomers) by
the excluded volume eect, macromolecular crowding accelerates peptide assembly and
has an eect analogous to that of an increase in peptide concentration (Fig. 13, left).
This trend is analogous to that observed experimentally by Munishkina et al., who have
studied the eect of increasing the PEG concentration on the -synuclein aggregation
process71.
On the other hand, when the aggregation mechanism is fast and proceeds directly from
monomers to bril, the process is diusion limited, and the thermodynamic stabilization
of oligomers is less important than the reduction in peptide mobility. In this case, the
bottleneck is not the formation of the nucleus; the rate-limiting step for peptides that
show a direct aggregation mechanism is the elongation of the bril. Therefore, in this
case macromolecular crowding is much less ecient in accelerating the self-association of
peptides than an equivalent increase in peptide concentration, since the peptides diusion
is hindered by the crowders (Fig.13, right).
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VI. CONCLUSION
Atomistic simulations of aggregation are limited by short time scale, while experimen-
tal approaches to amyloid bril formation have insucient spatial resolution. Coarse-
grained models of polypeptide aggregation sacrice atomistic detail to reach timescales
that allow the comparison with and interpretation of experimental data. The models pre-
sented in this chapter have shed light upon amyloid aggregation kinetics and mechanisms,
which is helpful to formulate a unied picture of the available experimental data.
The CGF model has only one tunable parameter, the dierence dE between the energy
of the amyloid-competent and the amyloid-protected state of the monomer37. Variations
of this parameter reproduce several aggregation scenarios, both under homogeneous and
heterogeneous conditions. It is important to highlight that the CGF model does not
mimic any particular amyloid (poly)peptide sequence. However, the dierent aggrega-
tion kinetics obtained with this model can be directly compared with experiments carried
out with specic proteins. In Table 3 are reviewed the principal characteristics of the
aggregation process for both the high and low amyloidogenic tendency, and in both cases
several examples of real amyloid-forming (poly)peptide sequences are listed. It is im-
portant to note that (coarse-grained) simulations, e.g., those with the CGF37 and Shea43
models, allow for the emulation of conditions and/or phenomena that are not accessible by
(standard) experiments. As an example, the possibility to change solely the intrinsic con-
formational landscape of a monomer without aecting the inter-monomer interactions is
an advantage of the (coarse-grained) simulation methods with respect to conventional ex-
perimental techniques such as mutagenesis and solvent-induced conformational changes,
by which it is not possible to decouple changes in intra from inter-molecular interactions.
In conclusion, a slight modication of the free energy prole of an extremely simpli-
ed model of an amphipathic peptide is sucient to observe a wide range of dierent
bril formation mechanisms, providing a unifying description of the heterogeneity of the
experimentally observed kinetics of amyloid bril formation.
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Fraction of
CGF peptides
Type of Rhydrophilic Rhydrophobic hydrophilic hydrophobic 
a bound to Reference
molecule [nm] [nm] [kcal/mol] [kcal/mol] lipid vesicles
lipid 0.31 0.3 -0.1 -1.265 0.87-0.90 50% 73
lipid 0.31 0.3 -0.1 -1.265 0.95 80% 74
surfactant 0.35 0.3 -0.1 -0.8 1 80
TABLE 1. Three-bead lipid and surfactants models used with CGF peptide model. aScaling
factor for the vdW interactions between lipids or surfactants and peptides. Dierent scaling is
used to model dierent systems, i.e., surfactants ( = 1), moderately attractive (  0:9) and
strongly attractive (  0:95) lipid bilayers.
Scaling of Number of Lag time t50 [ns]
peptide/lipid Amyloido- runs with with without
interactions genicity bril formation membrane membrane
0.87 high 10/10 11  1 19  3
interm. 29/29 89  29 56  15
low 17/20 958  503 124  28
very low 0/10 > 2000 318  133
0.90 high 10/10 10  1 19  3
interm. 30/30 69  23 56  15
low 0/20 > 2000 124  28
very low 0/20 > 2000 318  133
TABLE 2. Characteristic lag time of aggregation t50 for CGF peptide model for dierent
amyloidogenic tendency in the presence or absence of lipid vesicles73. Values in boldface are
signicantly larger in the presence of the vesicles
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high amyloidogenicity low amyloidogenicity Ref.
small nucleus large nucleus [37]
fast bril formation slow bril formation [37]
downhill micellar intermediates [37]
no intermediates protobrillar intermediates [50]
single pathway multiple pathways [50]
strong concentration dependence growth rate marginally dependent on concentration [37]
polymorphism under thermodynamic control polymorphism under kinetic control [64]
can promote membrane leakage does not promote membrane leakage [73]
slightly accelerated by membranes decelerated by membranes [73]
marginally inuenced by surfactants decelerated by surfactants [80]
not accelerated by macromolecular crowding accelerated by macromolecular crowding [81]
Phe-Phe, GNNQQNY, transthyretin, A42 A40, Sup35, prion protein, myoglobin -
TABLE 3. Inuence of amyloidogenic propensity on the aggregation kinetics and pathways of
the CGF model37. The last line lists some examples but it must be stressed that amyloidogenic
tendency strongly depends on external conditions, so that the same polypeptide sequence can
show drastically dierent amyloidogenic tendency depending on pH, temperature, etc.
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a)     b)     c)
d)     e)     f )
κ
Low β-sheet
propensity
High β−sheet
propensity
FIG. 1. Main coarse-grained models discussed in section II. a) Cuboid model39; b) tube model40;
c) lattice model41; d) CGF model37; e) Shea model43; f) Hall model42. Reprinted from36 with
permission by Elsevier.
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FIG. 2. The CGF model: sticks and beads representations of the monomer in the amyloid-
competent state  and the amyloid-protected state 37. The large spheres are hydrophobic
(black) and hydrophilic (gray), while the two dipoles are shown with small red and blue spheres.
The size of the spheres does not represent the actual van der Waals radii, which are 2.5 A for
the black and gray spheres and 2.0 A for the red and blue spheres. The  and  states of
the monomer are shown on top of the two corresponding minima of the free energy, plotted
as a function of the dihedral angle  of the two dipoles. Reprinted from50 with permission by
Elsevier.
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FIG. 3. The dotted line is the dihedral potential with a dE = -2.5 kcal/mol energy dierence
between amyloid-protected and amyloid-competent state. The ve continuous lines represent
the free energy prole of the isolated monomer for ve dierent dihedral potentials. Since the
peptide has only one degree of freedom, dE is close to the free-energy dierence between the two
aforementioned states. For instance, when dE = 0.0 kcal/mol, the  and  states are equally
populated, whereas for dE = -1.5, -2.0, and -2.25 kcal/mol, the  state is about 15, 39, and
64 times more populated than the  state, respectively. Reprinted from37 with permission by
Elsevier.
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FIG. 4. Inuence of amyloidogenic tendency on aggregation kinetics. (Left): Time series of the
fraction of ordered aggregation evaluated at four values of the amyloidogenic tendency, from
very prone to form brillar aggregates (dE = 0.0 kcal/mol) to marginal propensity (dE = -2.5
kcal/mol). Ten independent simulations are shown for each dE value. (Right): Fluorescence
intensity (degree of aggregation) of V18I (a), V18Q (b) and V18P (c) mutants of A40 (Ref.
49).
Note that the ns-s timescales in the CGF model simulations are much shorter than in the
experiments (hours) because of the much higher concentration in the former (8.5 mM) than in
the latter (120 M). Reprinted from37 (left) and49 (right) with permission by Elsevier (left) and
Jon Wiley & Sons (right).
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FIG. 5. Oligomer size histograms of the dE = -2.5 kcal/mol potential (top) and dE = 0.0
kcal/mol (bottom) calculated at the lag phase (left) and at the nal equilibrium (right). The
z-dimension represents the relative probability. Note that most of the results were obtained at
a concentration C = 8.5 mM which is the lowest value at which bril formation takes place
within a reasonable simulation time for the dE = -2.5 kcal/mol model (10 s in about 17 days
on a single Xeon 5410 processor). Reprinted from37 with permission by Elsevier.
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FIG. 6. Inuence of the amyloidogenicity parameter dE on the kinetics of the CGF model. The
time needed to reach 50% of the maximal amplitude t50 (black circles and y-axis legend on the
right) and the elongation rate (red squares and y-axis legend on the left) are displayed for seven
dE values. Symbols represent the average value of ten independent runs, and the error bars are
the maximum and minimum values. The broken line and the gray band indicate the average
and the maxmin values for the time of micelle formation, respectively. Reprinted from37 with
permission by Elsevier.
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FIG. 7. Aggregation state network. The size of the largest aggregate Nla and its number
of protolaments Npfla were used to cluster all simulation snapshots into states (i.e., nodes
of the network). The size and the colour of nodes correspond to the statistical weight and
the number of protolaments Npfla , respectively. Links are direct transitions within 0.5 ns of
Langevin dynamics. Note the much higher heterogeneity of protobrillar intermediates for the
-unstable (dE = -2.5 kcal/mol, bottom) as compared to the -stable (dE = -1.5 kcal/mol,
top) model. The insets show (proto)brillar structures that are representative of each region
of the aggregation state network. In these structures, monomers in the amyloid-competent
conformer  and amyloid-protected conformer  are in red and blue, respectively. Furthermore,
hydrophobic spheres are gray and hydrophlic spheres are not shown for visual clarity. Reprinted
from50 with permission by Elsevier.
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FIG. 8. Observed nucleation scenarios of the CGF peptide model. Black and white circles
represent the amyloid-competent conformer  and amyloid-protected conformer , respectively.
CGF peptides with high values of amyloidogenic tendency nucleate without intermediates, while
poorly amyloidogenic CGF peptides can nucleate either through micelle-sized oligomers (dE =
-2.25 kcal/mol) or transient oligomers larger than a micelle (dE = -2.5 kcal/mol). A further
stabilization (dE = -2.75 kcal/mol) of the protected state prevents bril formation within
the simulation time of about 20 s. M, micelle; N, nucleus; T, transient oligomer; F, bril.
Reprinted from37 with permission by Elsevier.
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FIG. 9. Inuence of peptide concentration on aggregation kinetics. (Left) Eect of concentration
on the lag phase time t50 (a) and elongation rate (b) for low and high values (dE = -2.5
kcal/mol, black circles; dE = 0.0 kcal/mol, green squares, respectively) of the amyloidogenic
tendency. The symbols represent the average value calculated from 15 simulations for dE
= -2.5 kcal/mol and ten simulations for dE = 0.0 kcal/mol. The error bars represent the
minimum and the maximum values. The vertical dotted line indicates the critical concentration
of micelle formation. (Right) Inuence of the initial monomeric concentration on the kinetics
of insulin bril formation as measured by Thioavin T uorescence58. Note that the higher
the concentration of monomeric insulin is at the beginning of the experiments, the shorter is
the lag phase and the faster is the elongation rate. Reprinted from37 (left) and58 (right) with
permission by Elsevier (left) and American Chemical Society (right).
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FIG. 10. Morphology dierentiation and kinetic control of bril polymorphism. (Left) Mor-
phologies of mature brils and prebrillar species. (Top) Mature brils display a 4-protolament
structure (4PF). The 4PF morphologies have dierent orientation of the protolaments, orga-
nization of up and down protolaments, and thickness of the bril. (Bottom) The prebril-
lar species are: the micellar oligomers M, consisting of -monomers (blue beads) aggregated
through hydrophobic forces; the 2-protolament protobril (2PP), and the 3-protolament
protobril (3PP), which are early stages of bril maturation, where the -monomers are de-
posited onto the lateral surface of the bril, and the -monomers make up the protolaments
(colored ribbons). (Right) Branched tree illustration of the morphology dierentiation pro-
cess as observed in the simulations. Reprinted from64 with permission by American Chemical
Society.
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FIG. 11. Comparison of CGF model simulations and experimental data on bril formation
in the presence of lipid vesicles. (Left) Simulation results. (Left, top) Inuence of peptide
amyloidogenicity on bril growth kinetics and vesicle leakage. A single parameter, the energy
dierence between amyloid-competent and amyloid-protected conformations of the peptides, is
varied in dierent simulations to tune amyloidogenicity. Time series of the average number of
ordered polar contacts between monomers (corresponding to the degree of brillation). (Left,
bottom) Average number of probes inside the vesicle, in the absence (black) or presence (colors)
of peptides, and for simulations where a preformed bril was used instead of dispersed peptides.
(Right) Experimental data: Eect of human islet amyloid polypeptide (hIAPP) bril growth on
membrane leakage69. Thioavin T uorescence intensity (Right, top) and induced membrane
leakage (Right, bottom) of three hIAPP samples (black curves), together with representative
traces for mouse IAPP variant which is known to be non-toxic amyloid polypeptide (gray
lines) and preformed hIAPP brils (dashed lines) are shown. The two vertical lines are shown
to facilitate comparison of the kinetic traces in top and bottom panel. Reprinted from73 (left)
and69 (right) with permission by Elsevier and by Copyright 2008 National Academy of Sciences,
U.S.A., respectively.
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FIG. 12. Amyloid aggregation in the presence and absence of surfactants. The number of
peptides in the largest aggregate is averaged over 20 runs at each simulation condition, i.e., for
each value of aggregation propensity (dE) and each surfactant/peptide concentration ratio (s:p).
Free peptides display fast aggregation without any noticeable lag phase. At surfactant:peptide
ratio of 4:1, peptides aggregate into brils, but aggregation is much slower for peptides with low
amyloidogenicity (see the inset for dE = -2.25 and surfactant:peptide ratio of 4:1, extended to 8
s). At a surfactant:peptide ratio of 8:1, aggregation is completely inhibited for dE = -2.0 and
-2.25 kcal/mol, while highly amyloidogenic peptides (dE = -1.5 kcal/mol) are barely aected.
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FIG. 13. The deviation of aggregation kinetics between crowded and bulk conditions depends
on the amyloidogenicity. The time t50, at which the growing bril has reached 50% of the
polar contacts of the mature bril, is shown as a function of concentration. Black circles are
t50 values calculated at dierent peptide concentrations in the absence of crowders, while red
squares are t50 values at dierent equivalent concentrations Ceq obtained by varying the number
of crowders. Symbols represent the average value of 10 independent runs and the error bars are
the minimum and maximum values. Reprinted from81 with permission by American Chemical
Society.
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